Does Earlier Antifungal Use Save ACLF Patients?

Acute-on-chronic liver failure (ACLF) carries a high risk of mortality for hospitalized patients. Fungal infections frequently complicate these cases and worsen the prognosis significantly. Therefore, implementing effective antifungal therapy in ACLF remains a top priority for hepatologists and critical care specialists. Recent evidence suggests that clinical suspicion should drive treatment decisions more than delayed laboratory investigations.

The Impact of Antifungal Therapy in ACLF

Clinicians often face a dilemma when treating systemic infections in liver failure. Should they wait for culture results or start treatment immediately? A recent study highlighted that suspicion-based antifungal therapy in ACLF significantly increased survival at 28 days. Specifically, patients who received preemptive treatment fared much better than those whose therapy depended on confirmed investigations. Consequently, this proactive approach addresses the rapid deterioration typically seen in ACLF patients.

Improving Outcomes via Early Intervention

Waiting for diagnostic confirmation can lead to fatal delays. Fungal pathogens often evade early detection in standard blood cultures. However, the study indicates that acting on clinical red flags prevents severe sepsis. Furthermore, early intervention stabilizes the patient’s hemodynamic status more effectively. Doctors should consider risk factors like prolonged antibiotic use or ICU stays when initiating therapy. Ultimately, early antifungal therapy in ACLF acts as a life-saving bridge during acute decompensation.

Frequently Asked Questions

Q1: Why is suspicion-based therapy better than waiting for lab results?

Lab tests for fungal infections often take several days to return results. Since ACLF patients deteriorate rapidly, waiting for confirmation can lead to missed treatment windows and higher mortality.

Q2: Does this approach increase the risk of antifungal resistance?

While over-prescribing is a concern, the 28-day survival benefit in high-risk ACLF patients outweighs the theoretical risk of resistance. Clinicians should still practice stewardship by re-evaluating therapy once results become available.

References

Ghabril M et al. In inpatients with acute-on-chronic liver failure, suspicion- vs. investigation-based antifungal therapy increased survival at 28 d. Ann Intern Med. 2026 May 05. doi: 10.7326/ANNALS-26-01051-JC. PMID: 42081819.
Verma N, et al. Empirical Antifungal Therapy Improves Survival in Patients With Acute-on-Chronic Liver Failure With Suspected Invasive Fungal Infections: A Pragmatic Randomized Trial. Am J Gastroenterol. 2025.
Jalan R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute-on-chronic liver failure. J Hepatol. 2021.